F. Hoffmann-La Roche Ltd (ROG) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

F. Hoffmann-La Roche Ltd (Roche) is a biotechnology company, which develops drugs and diagnostics that improve the standard of care in major disease areas. It provides pharmaceuticals in cancer, neuroscience, infection, immunology, ophthalmology, cardiovascular and metabolism, hematology, neurology and respiratory disease areas. The company also provides in vitro diagnostics and tissue-based cancer diagnostics, besides diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose and treat diseases. The company offers its products and services to hospitals, commercial diagnostic laboratories, healthcare professionals, researchers and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries all over the world. Roche is headquartered in Basel, Switzerland.

F. Hoffmann-La Roche Ltd (ROG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 11
List of Figures 17
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 18
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 19
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 20
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 21
F. Hoffmann-La Roche Ltd, Medical Devices Deals, 2012 to YTD 2018 23
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 24
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deal Details 48
Asset Purchase 48
Roche to Acquire Heat Elution Purification Technology from Lumora 48
Roche Acquires PETE Technology from AbVitro 49
Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 50
Roche To Acquire Gene Sequencing Technologies From Three Universities 51
Venture Financing 52
SutroVax Raises USD85 Million in Series C Venture Financing 52
Macrolide Pharma Raises USD20 Million in Venture Financing 54
NMD Pharma Raises USD46.7 Million in Series A Financing 55
Ideaya Biosciences Raises USD94 Million in Crossover Series B Venture Financing 56
Pandion Therapeutics Raises USD58 Million in Series A Finanicng 58
Allakos Raises USD100 Million in Series B Equity Financing 59
Vivet Therapeutics Raises USD41 Million in Series A Venture Financing 60
SutroVax Raises USD64 Million in Series B Financing 61
Tioma Therapeutics Raises USD86 Million in Series A Financing 62
Second Genome Raises USD8.4 Million in Extended Series B Financing 63
Second Genome Raises USD42.6 Million in Series B Financing 64
Lumos Pharma Raises USD34 Million in Series B Financing Round 66
Mission Therapeutics Raises USD85.7 Million in Financing Round 68
Biodesy Raises USD10 Million in Series B Financing 69
C4 Therapeutics Raises USD73 Million in Series A Financing Round 70
Millendo Therapeutics Raises USD62 Million in Series B Venture Financing 71
Minoryx Therapeutics Raises USD22 Million in Series A Financing Round 73
Corvus Pharma Raises USD75 Million in Series B Venture Financing 75
AveXis Raises USD65 Million in Venture Financing 77
SutroVax Raises USD22 Million in Series A Venture Financing 79
Stratos Genomics Raises Additional USD15 Million in Series B Financing 80
Allakos Secures USD27.95 Million in Venture Funding 81
Macrolide Pharma Raises USD22 Million in Series A Financing 82
Lysosomal Therapeutics Raises USD20 Million in Series A Financing 83
AveXis Raises USD10 Million in Series C Financing Round 84
CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 85
Curetis Raises USD18 Million in Extended Series B Venture Financing 86
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 88
Allakos Raises USD10 Million in Extended Series A Venture Financing 90
Epic Sciences Raises USD30 Million in Series C Venture Financing 91
Lysosomal Therapeutics Raises US$4.8 Million In Seed Financing 92
Alios BioPharma Raises US$41 Million In Series B Venture Financing 94
Eloxx Pharma Raises Funds Through Initial Tranche Of First Round Of Financing 95
Aileron Therapeutics Raises US$30 Million In Series E Financing 96
Mission Therapeutics Raises US$32 Million In Series B Financing 98
Biodesy Raises US$15 Million In Series A Financing 99
Seragon Raises US$30 Million In Series A Financing 100
Opsona Therapeutics Raises USD46.8 Million In Extended Series C Financing 101
Horizon Discovery Raises US$10.5 Million In Final Closing Of Series C Financing 103
Aileron Raises US$12 Million In Extended Series D Financing 105
Foundation Medicine Raises US$56 Million In Series B Financing 107
Allakos Raises US$32 Million In Series A Financing 109
Epic Sciences Raises US$13 Million In Series B Financing 110
Ambit Biosciences Raises US$25 Million In First Tranche Of Venture Financing 111
cCAM Biotherapeutics Raises US$6 Million In Series A Financing 113
Cytomx Therapeutics Raises Additional US$11 Million In Series B Financing 114
Santaris Pharma Raises US$12 Million In Venture Financing 115
Bina Technologies Raises USD1.2 Million in Venture Financing 117
GeneWeave Raises US$12 Million In Series A Financing Round 118
Ariosa Diagnostics Secures USD52.7 Million in Series C Funding Round 119
Partnerships 120
Roche Enters into Licensing Agreement with Becton Dickinson 120
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 121
Microbiotica Enters into Collaboration Agreement with Genentech 122
Tesaro Enters into Collaboration Agreement with Genentech 123
Five Prime Therapeutics Enters into Partnership with Roche 124
Pierre Fabre Expands Agreement with Roche for W0101 125
Lodo Therapeutics Enters into Agreement with Genentech 126
NeoImmuneTech and Genexine Enter into Agreement with Roche 127
4D Molecular Therapeutics Expands Ophthalmology Partnership Agreement with Roche 128
BioMed X Enters into Research Agreement with F. Hoffmann-La Roche 129
Cipla and Roche Products Enter into Distribution Agreement 130
Tesaro Enters into Partnership with Genentech 131
Emulate Enters into Agreement with Roche 132
Forty Seven Enters into Agreement with Genentech 133
Syndax Pharma Enters into Agreement with Genentech 134
Idorsia Enters into Research Agreement with Roche 135
DiCE Molecules Enters into Research Agreement with Genentech 136
Boehringer Ingelheim Enters into Co-Development Agreement with Roche 137
Biothera Pharma Enters into Collaboration Agreement with Genentech 138
Inotrem Enters into Research Agreement with Roche Diagnostics 139
Warp Drive Bio Enters into Partnership with Roche 140
Chugai Pharma Enters into Research Agreement with National Cancer Center Japan 141
Seattle Genetics Enters into Agreement with Genentech 142
Roche and Institut Curie Enter into Agreement 143
Epizyme Enters into Agreement with Genentech 144
Inovio Pharma Enters into Agreement with Genentech 145
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 146
Bavarian Nordic Enters into Agreement with Roche 147
Exelixis Enters into Agreement with Roche 148
Amunix Operating Enters into R&D Agreement with Genentech 149
BioNTech Enters into Agreement with Genentech 150
Gradalis Enters into Agreement with Genentech 151
G1 Therapeutics Enters into Agreement with Genentech 152
F. Hoffmann-La Roche Expands its Distribution Agreement with MilliporeSigma 153
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 154
Foundation Medicine Enters into Agreement with Sarah Cannon Research Institute 155
Charles River Laboratories International Extends Agreement with Genentech 156
Epizyme Enters into Agreement with Foundation Medicine 157
BioLineRx Enters into Agreement with Genentech 158
Epizyme Enters into Agreement with Genentech 159
Foundation Medicine Enters into Agreement with AstraZeneca 160
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 161
Chugai Pharmaceutical Enters into Agreement with Osaka University 163
Foundation Medicine Partners with AstraZeneca 164
Astex Pharma Enters into Agreement with Genentech 165
Clovis Oncology Enters into Agreement with Genentech 166
Janssen Research & Development Enters into Agreement with Genentech 167
Kite Pharma Enters into Agreement with Genentech 168
Eli Lilly Enters into Agreement with Roche Diagnostics International 169
Lead Discovery Center to Enter into Drug Discovery Agreement with Roche 170
F. Hoffmann-La Roche Enters into Research Agreement with Catalent 171
Genticel Enters into Agreement with Roche Molecular Systems 172
C4 Therapeutics Enters into Partnership with Roche Pharma 173
PeptiDream Enters into Agreement with Genentech 174
Foundation Medicine Enters into Agreement with Mirati Therapeutics 175
Roche Enters into Agreement with SQZ Biotech 176
DexTech Medical Enters into Research Agreement with Roche 177
Roche Extends Agreement with Amunix for XTEN technology 178
Corvus Pharma Expands its Agreement with Genentech 179
Roche Enters into Agreement with National Institute for Public Health and the Environment 180
Janus Biotherapeutics Enters into Agreement with Roche 181
Immune Design Enters into Clinical Trial Collaboration with Genentech 182
Handok Enters into Agreement with Korea Roche 183
WaferGen Bio-systems Enters into Research Agreement with Genentech 184
Bina Technologies Enters into Agreement with AstraZeneca 185
Ventana Medical Enters into Agreement with Astellas Pharma to Develop Novel Automated Tissue Diagnostics 186
Roche Plans to Enter into Agreement for Immuno-Oncology Therapies 187
Sigma-Aldrich Enters into Distribution Agreement with Roche 188
Celldex Therapeutics Enters into Agreement with Roche 189
Roche Enters into Development Agreement with BioMed X 190
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 191
Roche Amends R&D Agreement with Foundation Medicine 192
23andMe Partners with Genentech 193
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 194
Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 195
Molecular Devices Enters into Co-Development Agreement with Roche Diagnostics 196
Cardiorentis Enters into Co-Development Agreement with Roche for Ularitide 197
Genentech Enters into Research Agreement with NewLink Genetics 198
Pharmathen Pharma Enters into Co-Marketing Agreement with InterMune 199
Roche NimbleGen Enters into Co-Development Agreement with Garvan Institute of Medical Research 200
Roche Enters into Agreement with AmorChem to Develop Myotonic Dystrophy Treatment 201
AstraZeneca Enters into Co-Development Agreement with Roche 202
Advanced Biological Labs Extends Co-Promotion Agreement with Roche Diagnostics 203
Bioprocessing Technology Institute Enters Into Partnership with F. Hoffmann-La Roche 204
Bioprocessing Tech Institute Enters Into Agreement with Roche to Develop Cancer Therapeutics 205
Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 206
Roche Enters into Co-Development Agreement with Stratos Genomics 207
AUT University Forms Joint Venture with Roche Diagnostics 208
Ferring Pharma Enters into Co-Development Agreement with Roche 209
Roche to Form Joint Venture with Inception Sciences and Versant Ventures 210
Bind Therapeutics Enters into Research Agreement with Roche for Accurins 211
Foundation Medicine Enters Into Distribution Agreement With Laboratorios Leti 212
Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 213
Roche Enters Into Research Agreement With Laval University 214
Santaris Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For RNA-Targeted Medicines 215
Santaris Enters Into Co-Development Agreement With Roche For RNA-Targeted Drugs 216
Pierre Fabre Enters into Agreement with Roche for NeoRecormon 217
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 218
Advanced Biological Labs And Roche Diagnostics Enter Into Agreement To Promote Sequencing, Genotyping And Drug Resistance Products 219
Ascendis Pharma Enters Into Collaboration Agreement with Genentech 220
AstraZeneca, Roche And MedChemica Enter Into Agreement To Accelerate Drug Development 221
Macrocyclics Enters Into Co-Development Agreement With Roche For Chelating Agents 222
Santaris Pharma Enters Into Agreement With Bristol-Myers Squibb For RNA-Targeted Medicines 223
Roche Enters Into Agreement With Ascletis To Develop HCV Drug Danoprevir 224
Roche Enters Into Co-Development Agreement With Isis Pharma For Huntingtons Disease Treatment 225
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 226
Roche Enters Into Co-Development Agreement With BioLamina For Cell Culture Systems 227
Roche Enters into Technology Transfer Agreement with Emcure Pharma for Two Patented Cancer Drugs 228
RQx Pharma Enters Into Drug Discovery Agreement With Genentech 229
ProMining Therapeutics Enters Into Agreement With Roche To Discover Small Molecule Therapeutics 230
Redbiotec Enters Into Co-Development Agreement With Roche Diagnostics 231
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 232
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 233
Roche Enters Forms Joint Venture with Versant Ventures and Inception Sciences 234
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 235
Roche Enters Into Co-Development Agreement With Areva Med 236
Handok Enters Into Co-Marketing Agreement With Roche For Madopar 237
Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 238
Roche, ANRS, Baylor Researh Institute And Inserm Transfert Enter Into Co-Development Agreement For Therapeutic Vaccines 239
Chong Kun Dang Pharma Enters Into Co-Marketing Agreement With Roche For Six Products 241
Constellation Pharma Enters Into Co-Development Agreement With Genentech 242
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 243
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 244
Licensing Agreements 245
Genentech Enters into Licensing Agreement with Kineta Chronic Pain 245
Abcam Enters into Licensing Agreement with Roche 246
Roche Enters into Licensing Agreement with MacroGenics 247
Roche Exercises Option for Licensing Agreement with Immatics 248
Roche Enters into Licensing Agreement with Confo Therapeutics 249
Ionis Pharma Enters into License Agreement with Roche for IONIS-HTTRx 250
Roche Enters into Licensing Agreement with Ncardia 251
Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 252
Roche Enters into Licensing Agreement with Halozyme Therapeutics 254
Roche to Enter into Licensing Agreement with Pharmstandard 255
JW Pharma Enters into Licensing Agreement with Chugai Pharma 256
Roche to Enter into Licensing Agreement with Bristol-Myers Squibb 257
Mylan Enters into Licensing Agreement with Genentech and Roche 258
Chugai Pharma Enters into Licensing Agreement with SBI Pharma 259
CiVi Biopharma Enters into Licensing Agreement with F. Hoffmann-La Roche 260
Roche Enters into Licensing Agreement with ImmuNext 261
Genentech Enters into Licensing Agreement with Novimmune 262
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 263
Genentech to Enter into Licensing Agreement with Hanmi Pharma 264
Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 265
Denali Therapeutics Enters Into Licensing Agreement With Genentech 266
Roche Enters into Licensing Agreement with Eleven Biotherapeutics 267
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 268
Chugai Pharma Enters into Licensing Agreement with Two Cells 269
Roche Enters into Licensing Agreement with Blueprint Medicines 270
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 272
F. Hoffmann-La Roche Enters into Licensing Agreement with Shionogi 273
Roche Enters into Licensing Agreement with University of British Columbia and Vancouver Coastal Health Research Institute 274
F. Hoffmann-La Roche Entered into Licensing Agreement with Proximagen 275
Roche Enters into Licensing Agreement with Cellular Dynamics 276
Genentech Enters into Licensing Agreement with Nimbus Therapeutics 277
Genentech Expands Licensing Agreement with Arvinas 278
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 279
Genentech Enters into Licensing Agreement with Almac Discovery 280
Vifor Pharma Expands Licensing Agreement with Roche 281
Curadev Pharma Enters into Licensing Agreement with Roche 282
Phylogica Extends Licensing Agreement with Genentech 283
Genentech to Terminate Licensing Agreement with NewLink Genetics for NLG919 284
Roche Amends Licensing Agreement with Chugai Pharma 286
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 287
Ark Biosciences Enters into Licensing Agreement with Roche for AK0529 288
Chugai Pharma Enters into Licensing Agreement with Roche 289
Roche Expands its Licensing Agreement with Discuva 290
Roche Enters Into Licensing Agreement With Prothena 291
Isarna Therapeutics Enters Into Licensing Agreement With Santaris Pharma To Develop Oligonucleotides For TGF--Mediated Diseases 293
Ocera Therapeutics Enters Into Technology Transfer and License Agreement With F. Hoffmann-La Roche 294
Coherus BioSciences Enters into Licensing Agreement with Genentech 295
RaNA Therapeutics Enters Into Licensing Agreement With Santaris Pharma To Develop RNA-Targeted Medicines 296
Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 297
Santaris Pharma Amends Licensing Agreement With miRagen Therapeutics 298
Clementia Pharma Enters into Licensing Agreement with F. Hoffmann-La Roche 299
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 301
Dutalys Enters Into Licensing Agreement With Global Pharma Company 302
Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 303
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 304
Roche Enters Into Licensing Agreement With Galaxy Biotech For Oncology Program 305
Roche Enters Into Licensing Agreement With Savira Pharma 307
Novogen Enters into Licensing Agreement with Genentech for GDC-0084 308
Maruho Enters into Licensing Agreement with Chugai Pharma 309
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 310
Genentech Enters into Licensing Agreement with Carmot Therapeutics 311
Roche Enters into Licensing Agreement with Amgen 312
F. Hoffmann-La Roche Enters into Licensing Agreement with Pieris Pharma 313
Roche Enters into Licensing Agreement with Dalcor Pharma 314
4D Molecular Therapeutics Enters into Licensing Agreement with Roche 315
Roche Molecular Enters into Licensing Agreement with Qiagen 316
Roche Enters into Licensing Agreement with Meiji Seika Pharma and Fedora Pharma 317
EpiVax Enters into Licensing Agreement with Chugai Pharma 318
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 319
Roche To Enter Into Licensing Agreement With Medicines Patent Pool For Saquinavir 320
Afraxis Enters Into Licensing Agreement With Genentech 321
Research Ventures & Licensing Enters Into Licensing Agreement With Santaris Pharma 322
Techpool Bio-Pharma Enters Into Licensing Agreement With Roche For Antineoplastic Drug 323
Roche Enters Into Licensing Agreement With Seaside Therapeutics For mGluR5 Antagonists 324
AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 325
Roche Extends Licensing Agreement With Genedata 327
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 328
Equity Offering 329
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 329
Foundation Medicine Raises USD250 Million in Private Placement of Shares 330
Ariosa Diagnostics Withdraws IPO 331
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 332
InterMune Completes Public Offering Of Shares For US$282.5 Million 333
InterMune Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For US$97.2 Million 334
Foundation Medicine Completes IPO Of Shares For US$122 Million 335
InterMune Completes Public Offering Of Common Stock For US$154 Million 336
Debt Offering 337
Roche Prices Public Offering of Bonds Due 2020 for USD600 Million 337
Roche Prices Public Offering of 0.875% Bonds Due 2025 for USD1.14 Billion 338
Roche Plans to Raise USD850 Million in Public Offering of Notes 339
Roche Plans to Raise USD500 Million in Public Offering of Bonds 340
Roche Plans to Raise USD1.3 Billion in Public Offering of Bonds Due 2021 341
Roche Plans to Raise USD1.3 Billion in Public Offering of Bonds Due 2024 342
Roche Plans to Raise USD300 Million in Public Offering of Bonds 343
Roche Plans to Raise USD1.5 Billion in Public Offering of Bonds 344
InterMune Completes Public Offering Of Notes Due 2017 For US$137 Million 345
Roche Completes Public Offering Of Bonds Due 2018 For US$658 Million 347
Roche Completes Public Offering Of Bonds Due 2022 For US$548 Million 348
Roche Completes Public Offering Of Bonds Due 2013 For US$438 Million 349
Roche Completes Public Offering Of Bonds Due 2018 For US$1.32 Billion 350
Asset Transactions 351
Recipharm Acquires Manufacturing Facility from Roche 351
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 352
Patheon Acquires API Manufacturing Site, South Carolina from Roche 353
F. Hoffmann-La Roche May Sell its Diabetes Care Business 354
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 355
Atnahs Pharma Acquires Naprosyn, Anaprox and Toradol from Roche 356
Pediapharm Acquires Naproxen Suspension from Roche 357
Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD497 Million 358
Vidara Therapeutics International Acquires Actimmune From InterMune For US$55 Million 360
RIEMSER Arzneimittel Acquires Worldwide Rights Of Ostac From Roche 362
Acquisition 363
Roche to Acquire Remaining Stake in Foundation Medicine for USD2.4 Billion 363
Roche to Acquire Ignyta for USD1.7 Billion 364
Roche Acquires ForSight VISION4 from ForSight Labs 366
Noritsu Koki to Acquire 64.7% Stake in Genentech for USD27 Million 367
Roche Acquires Tensha Therapeutics 368
Pacific Biosciences May Sell Itself 369
Roche Acquires Kapa Biosystems 370
Roche Acquires Adheron Therapeutics 371
Roche Acquires CAPP Medical 372
Roche Acquires Majority Stake in Foundation Medicine for USD1.03 Billion 373
Roche May Acquire BioMarin Pharma 375
Roche Acquires Trophos for USD386 Million 376
Roche Acquires Signature Diagnostics 378
Roche Acquires Bina Technologies 379
Roche Acquires Dutalys for USD489 million 380
Tetraphase Pharma May Sell Itself 381
Roche Acquires InterMune for USD8.3 Billion 382
Roche Acquires Santaris Pharma for USD450 Million 384
Roche Completes Acquisition of Seragon Pharma for USD1.72 Billion 386
Roche May Acquire 40% Stake in Chugai Pharma 387
F. Hoffmann-La Roche Completes Acquisition of Iquum for USD450 Million 388
Roche Diagnostics Acquires Genia for up to USD350 Million 389
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technologys Spin-Out Companies 390
Roche Rumored to Acquire BioMarin Pharma for USD13.5 Billion 391
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 392
Takeda Completes Acquisition Of Remaining 87.5% Stake In Envoy Therapeutics For Up To US$140 Million 394
F. Hoffmann-La Roche Ltd - Key Competitors 396
F. Hoffmann-La Roche Ltd - Key Employees 397
F. Hoffmann-La Roche Ltd - Locations And Subsidiaries 398
Head Office 398
Other Locations & Subsidiaries 398
Recent Developments 409
Strategy And Business Planning 409
May 24, 2018: Prothena Announces Reorganization to Focus Resources on Advancing Neuroscience Pipeline 409
Nov 22, 2017: Roche expands its Kaiseraugst site and opens new IT innovation centre 410
Financial Announcements 411
Feb 01, 2018: Roche reports good results in 2017 411
Oct 19, 2017: Roche reports strong sales growth in the first nine months of 2017 412
Jul 27, 2017: Roche reports strong performance in the first half of 2017 416
Apr 27, 2017: Roche reports a good start in 2017 418
Feb 01, 2017: Roche reports good results in 2016 420
Corporate Communications 423
Mar 08, 2018: Changes to the Roche Enlarged Corporate Executive Committee 423
Legal and Regulatory 424
May 03, 2018: Roche wins reprieve as Novartis biosimilar delayed in U.S. 424
Jan 25, 2018: Roche and Novartis accused of anti-competitive conduct by EU court 425
Dec 15, 2017: European Commission closes infringement procedure against Roche 426
Government and Public Interest 427
Dec 01, 2017: Roche Supports FDA Communication about Potential for Biotin Interference with Lab Tests 427
Product News 428
Nov 27, 2017: Roche launches HyperCap Target Enrichment Portfolio, a fully integrated and streamlined NGS sample prep solution for research use 428
10/12/2017: Roche Registration receives CHMP positive opinion for Pegasys 429
10/03/2017: RG7916 Increased SMN Protein Production in SUNFISH Clinical Trial in Patients with Type 2/3 Spinal Muscular Atrophy 430
09/29/2017: FDA Grants Priority Review for Genentechs Perjeta (Pertuzumab) for Adjuvant Treatment of HER2-Positive Early Breast Cancer 431
06/22/2017: Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntingtons Disease Completed and Open-Label Extension Study to Open in 2H 2017 432
06/20/2017: Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden 433
06/19/2017: Xolair added to seven Canadian public drug plans to treat chronic idiopathic urticaria (hives) 434
06/16/2018: Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CureSMA Conference 435
05/08/2018: Scientists investigate new strategy to treat spinal muscular atrophy in infants 436
May 08, 2017: Roche launches AVENIO ctDNA Analysis Kits for Oncology Research 437
04/18/2018: Preliminary Study Suggests Drug May Help Babies with Spinal Muscular Atrophy 438
04/15/2018: Genentech Provided Update on RG-7916 439
03/24/2017: Anti-IgE antibody formulation "Zolare" acquired additional indication as a treatment for idiopathic chronic urticaria 440
03/15/2018: FIREFISH Transitions into Pivotal Phase 441
03/01/2018: IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntingtons Disease 442
01/29/2018: FDA grants Breakthrough Therapy Designation for Roches balovaptan in autism spectrum disorder 443
01/27/2018: Preliminary Data from FIREFISH trial in Type 1 SMA Infants Presented at the International Scientific Congress on Spinal Muscular Atrophy 444
01/26/2017: First immunotherapy treatment for bladder cancer fast-tracked under UKs Early Access to Medicines Scheme (EAMS) 446
01/23/2018: Data from RG7916 Programs in SMA to be Presented at the International Scientific Congress on Spinal Muscular Atrophy 447
Product Approvals 448
Feb 12, 2018: Roches Pegasys Rejects For Use Within NHS Scotland 448
Jun 12, 2017: Scottish Medicine Consortium (SMC) rejects Perjeta (pertuzumab) for NHS use for women with advanced, terminal HER2-positive breast cancer 449
Feb 17, 2017: New Drug Application Filed for Immune Checkpoint Inhibitor, Atezolizumab - First Application as anti PD-L1 Antibody for the Treatment of Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer in Japan 450
Jan 09, 2017: FDA grants Roches cancer immunotherapy TECENTRIQ (atezolizumab) Priority Review in additional type of advanced bladder cancer 451
Jan 09, 2017: NICE Recommends Pertuzumab for the Neoadjuvant Treatment of HER2-positive Breast Cancer 452
Jan 06, 2017: RG7916 Granted Orphan Drug Designation in the U.S. for the Treatment of Spinal Muscular Atrophy 453
Clinical Trials 454
Apr 24, 2018: Preliminary Clinical Data from FIREFISH Trial in Type 1 SMA Patients Presented at the American Academy of Neurology Annual Meeting 454
Dec 13, 2017: New drug could halt progression of Huntingtons disease 455
Oct 25, 2017: Anti-Cancer Agent "Perjeta" Filed for Additional Indication of Adjuvant Therapy for HER2-Positive Early Breast Cancer 456
Oct 12, 2017: Spinal Muscular Atrophy Program Advances into Pivotal Study in SMA Patients 457
Sep 16, 2017: Novartis Xolair confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption 458
Sep 08, 2017: New study opens for rheumatoid arthritis patients who do not respond to standard treatment 459
Jul 01, 2017: Preliminary Phase 2 Data from Spinal Muscular Atrophy Program Presented at CureSMA Conference 460
Jun 05, 2017: APHINITY study shows Roches Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer 461
Mar 06, 2017: MorphoSys Partner to Start New Phase 3 Clinical Trials with Gantenerumab in Alzheimers Disease 463
Mar 01, 2017: Phase III APHINITY Study Shows Genentechs Perjeta Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer without their Disease Returning Compared to Herceptin and Chemotherapy 464
Feb 17, 2017: Phase II Study Supports Potential for Genentechs Tecentriq (Atezolizumab) Plus Avastin (Bevacizumab) for People with Locally Advanced or Metastatic Renal Cell Carcinoma 466
Jan 05, 2017: PTC Therapeutics Announces Initiation of FIREFISH Study in Infant (Type I) SMA Patients 468
Other Significant Developments 469
Apr 26, 2018: Roche reports a strong start in 2018 469
Mar 02, 2018: Roche achieves two major milestones in the evolution of decision support platform 471
Appendix 472
Methodology 472
About GlobalData 472
Contact Us 472
Disclaimer 472

List Of Tables

List of Tables
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 18
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 19
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 20
F. Hoffmann-La Roche Ltd, Deals By Therapy Area, 2012 to YTD 2018 21
F. Hoffmann-La Roche Ltd, Medical Devices Deals, 2012 to YTD 2018 23
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 24
Roche to Acquire Heat Elution Purification Technology from Lumora 48
Roche Acquires PETE Technology from AbVitro 49
Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 50
Roche To Acquire Gene Sequencing Technologies From Three Universities 51
SutroVax Raises USD85 Million in Series C Venture Financing 52
Macrolide Pharma Raises USD20 Million in Venture Financing 54
NMD Pharma Raises USD46.7 Million in Series A Financing 55
Ideaya Biosciences Raises USD94 Million in Crossover Series B Venture Financing 56
Pandion Therapeutics Raises USD58 Million in Series A Finanicng 58
Allakos Raises USD100 Million in Series B Equity Financing 59
Vivet Therapeutics Raises USD41 Million in Series A Venture Financing 60
SutroVax Raises USD64 Million in Series B Financing 61
Tioma Therapeutics Raises USD86 Million in Series A Financing 62
Second Genome Raises USD8.4 Million in Extended Series B Financing 63
Second Genome Raises USD42.6 Million in Series B Financing 64
Lumos Pharma Raises USD34 Million in Series B Financing Round 66
Mission Therapeutics Raises USD85.7 Million in Financing Round 68
Biodesy Raises USD10 Million in Series B Financing 69
C4 Therapeutics Raises USD73 Million in Series A Financing Round 70
Millendo Therapeutics Raises USD62 Million in Series B Venture Financing 71
Minoryx Therapeutics Raises USD22 Million in Series A Financing Round 73
Corvus Pharma Raises USD75 Million in Series B Venture Financing 75
AveXis Raises USD65 Million in Venture Financing 77
SutroVax Raises USD22 Million in Series A Venture Financing 79
Stratos Genomics Raises Additional USD15 Million in Series B Financing 80
Allakos Secures USD27.95 Million in Venture Funding 81
Macrolide Pharma Raises USD22 Million in Series A Financing 82
Lysosomal Therapeutics Raises USD20 Million in Series A Financing 83
AveXis Raises USD10 Million in Series C Financing Round 84
CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 85
Curetis Raises USD18 Million in Extended Series B Venture Financing 86
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 88
Allakos Raises USD10 Million in Extended Series A Venture Financing 90
Epic Sciences Raises USD30 Million in Series C Venture Financing 91
Lysosomal Therapeutics Raises US$4.8 Million In Seed Financing 92
Alios BioPharma Raises US$41 Million In Series B Venture Financing 94
Eloxx Pharma Raises Funds Through Initial Tranche Of First Round Of Financing 95
Aileron Therapeutics Raises US$30 Million In Series E Financing 96
Mission Therapeutics Raises US$32 Million In Series B Financing 98
Biodesy Raises US$15 Million In Series A Financing 99
Seragon Raises US$30 Million In Series A Financing 100
Opsona Therapeutics Raises USD46.8 Million In Extended Series C Financing 101
Horizon Discovery Raises US$10.5 Million In Final Closing Of Series C Financing 103
Aileron Raises US$12 Million In Extended Series D Financing 105
Foundation Medicine Raises US$56 Million In Series B Financing 107
Allakos Raises US$32 Million In Series A Financing 109
Epic Sciences Raises US$13 Million In Series B Financing 110
Ambit Biosciences Raises US$25 Million In First Tranche Of Venture Financing 111
cCAM Biotherapeutics Raises US$6 Million In Series A Financing 113
Cytomx Therapeutics Raises Additional US$11 Million In Series B Financing 114
Santaris Pharma Raises US$12 Million In Venture Financing 115
Bina Technologies Raises USD1.2 Million in Venture Financing 117
GeneWeave Raises US$12 Million In Series A Financing Round 118
Ariosa Diagnostics Secures USD52.7 Million in Series C Funding Round 119
Roche Enters into Licensing Agreement with Becton Dickinson 120
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 121
Microbiotica Enters into Collaboration Agreement with Genentech 122
Tesaro Enters into Collaboration Agreement with Genentech 123
Five Prime Therapeutics Enters into Partnership with Roche 124
Pierre Fabre Expands Agreement with Roche for W0101 125
Lodo Therapeutics Enters into Agreement with Genentech 126
NeoImmuneTech and Genexine Enter into Agreement with Roche 127
4D Molecular Therapeutics Expands Ophthalmology Partnership Agreement with Roche 128
BioMed X Enters into Research Agreement with F. Hoffmann-La Roche 129
Cipla and Roche Products Enter into Distribution Agreement 130
Tesaro Enters into Partnership with Genentech 131
Emulate Enters into Agreement with Roche 132
Forty Seven Enters into Agreement with Genentech 133
Syndax Pharma Enters into Agreement with Genentech 134
Idorsia Enters into Research Agreement with Roche 135
DiCE Molecules Enters into Research Agreement with Genentech 136
Boehringer Ingelheim Enters into Co-Development Agreement with Roche 137
Biothera Pharma Enters into Collaboration Agreement with Genentech 138
Inotrem Enters into Research Agreement with Roche Diagnostics 139
Warp Drive Bio Enters into Partnership with Roche 140
Chugai Pharma Enters into Research Agreement with National Cancer Center Japan 141
Seattle Genetics Enters into Agreement with Genentech 142
Roche and Institut Curie Enter into Agreement 143
Epizyme Enters into Agreement with Genentech 144
Inovio Pharma Enters into Agreement with Genentech 145
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 146
Bavarian Nordic Enters into Agreement with Roche 147
Exelixis Enters into Agreement with Roche 148
Amunix Operating Enters into R&D Agreement with Genentech 149
BioNTech Enters into Agreement with Genentech 150
Gradalis Enters into Agreement with Genentech 151
G1 Therapeutics Enters into Agreement with Genentech 152
F. Hoffmann-La Roche Expands its Distribution Agreement with MilliporeSigma 153
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 154
Foundation Medicine Enters into Agreement with Sarah Cannon Research Institute 155
Charles River Laboratories International Extends Agreement with Genentech 156
Epizyme Enters into Agreement with Foundation Medicine 157
BioLineRx Enters into Agreement with Genentech 158
Epizyme Enters into Agreement with Genentech 159
Foundation Medicine Enters into Agreement with AstraZeneca 160
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 161
Chugai Pharmaceutical Enters into Agreement with Osaka University 163
Foundation Medicine Partners with AstraZeneca 164
Astex Pharma Enters into Agreement with Genentech 165
Clovis Oncology Enters into Agreement with Genentech 166
Janssen Research & Development Enters into Agreement with Genentech 167
Kite Pharma Enters into Agreement with Genentech 168
Eli Lilly Enters into Agreement with Roche Diagnostics International 169
Lead Discovery Center to Enter into Drug Discovery Agreement with Roche 170
F. Hoffmann-La Roche Enters into Research Agreement with Catalent 171
Genticel Enters into Agreement with Roche Molecular Systems 172
C4 Therapeutics Enters into Partnership with Roche Pharma 173
PeptiDream Enters into Agreement with Genentech 174
Foundation Medicine Enters into Agreement with Mirati Therapeutics 175
Roche Enters into Agreement with SQZ Biotech 176
DexTech Medical Enters into Research Agreement with Roche 177
Roche Extends Agreement with Amunix for XTEN technology 178
Corvus Pharma Expands its Agreement with Genentech 179
Roche Enters into Agreement with National Institute for Public Health and the Environment 180
Janus Biotherapeutics Enters into Agreement with Roche 181
Immune Design Enters into Clinical Trial Collaboration with Genentech 182
Handok Enters into Agreement with Korea Roche 183
WaferGen Bio-systems Enters into Research Agreement with Genentech 184
Bina Technologies Enters into Agreement with AstraZeneca 185
Ventana Medical Enters into Agreement with Astellas Pharma to Develop Novel Automated Tissue Diagnostics 186
Roche Plans to Enter into Agreement for Immuno-Oncology Therapies 187
Sigma-Aldrich Enters into Distribution Agreement with Roche 188
Celldex Therapeutics Enters into Agreement with Roche 189
Roche Enters into Development Agreement with BioMed X 190
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 191
Roche Amends R&D Agreement with Foundation Medicine 192
23andMe Partners with Genentech 193
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 194
Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 195
Molecular Devices Enters into Co-Development Agreement with Roche Diagnostics 196
Cardiorentis Enters into Co-Development Agreement with Roche for Ularitide 197
Genentech Enters into Research Agreement with NewLink Genetics 198
Pharmathen Pharma Enters into Co-Marketing Agreement with InterMune 199
Roche NimbleGen Enters into Co-Development Agreement with Garvan Institute of Medical Research 200
Roche Enters into Agreement with AmorChem to Develop Myotonic Dystrophy Treatment 201
AstraZeneca Enters into Co-Development Agreement with Roche 202
Advanced Biological Labs Extends Co-Promotion Agreement with Roche Diagnostics 203
Bioprocessing Technology Institute Enters Into Partnership with F. Hoffmann-La Roche 204
Bioprocessing Tech Institute Enters Into Agreement with Roche to Develop Cancer Therapeutics 205
Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 206
Roche Enters into Co-Development Agreement with Stratos Genomics 207
AUT University Forms Joint Venture with Roche Diagnostics 208
Ferring Pharma Enters into Co-Development Agreement with Roche 209
Roche to Form Joint Venture with Inception Sciences and Versant Ventures 210
Bind Therapeutics Enters into Research Agreement with Roche for Accurins 211
Foundation Medicine Enters Into Distribution Agreement With Laboratorios Leti 212
Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 213
Roche Enters Into Research Agreement With Laval University 214
Santaris Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For RNA-Targeted Medicines 215
Santaris Enters Into Co-Development Agreement With Roche For RNA-Targeted Drugs 216
Pierre Fabre Enters into Agreement with Roche for NeoRecormon 217
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 218
Advanced Biological Labs And Roche Diagnostics Enter Into Agreement To Promote Sequencing, Genotyping And Drug Resistance Products 219
Ascendis Pharma Enters Into Collaboration Agreement with Genentech 220
AstraZeneca, Roche And MedChemica Enter Into Agreement To Accelerate Drug Development 221
Macrocyclics Enters Into Co-Development Agreement With Roche For Chelating Agents 222
Santaris Pharma Enters Into Agreement With Bristol-Myers Squibb For RNA-Targeted Medicines 223
Roche Enters Into Agreement With Ascletis To Develop HCV Drug Danoprevir 224
Roche Enters Into Co-Development Agreement With Isis Pharma For Huntingtons Disease Treatment 225
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 226
Roche Enters Into Co-Development Agreement With BioLamina For Cell Culture Systems 227
Roche Enters into Technology Transfer Agreement with Emcure Pharma for Two Patented Cancer Drugs 228
RQx Pharma Enters Into Drug Discovery Agreement With Genentech 229
ProMining Therapeutics Enters Into Agreement With Roche To Discover Small Molecule Therapeutics 230
Redbiotec Enters Into Co-Development Agreement With Roche Diagnostics 231
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 232
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 233
Roche Enters Forms Joint Venture with Versant Ventures and Inception Sciences 234
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 235
Roche Enters Into Co-Development Agreement With Areva Med 236
Handok Enters Into Co-Marketing Agreement With Roche For Madopar 237
Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 238
Roche, ANRS, Baylor Researh Institute And Inserm Transfert Enter Into Co-Development Agreement For Therapeutic Vaccines 239
Chong Kun Dang Pharma Enters Into Co-Marketing Agreement With Roche For Six Products 241
Constellation Pharma Enters Into Co-Development Agreement With Genentech 242
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 243
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 244
Genentech Enters into Licensing Agreement with Kineta Chronic Pain 245
Abcam Enters into Licensing Agreement with Roche 246
Roche Enters into Licensing Agreement with MacroGenics 247
Roche Exercises Option for Licensing Agreement with Immatics 248
Roche Enters into Licensing Agreement with Confo Therapeutics 249
Ionis Pharma Enters into License Agreement with Roche for IONIS-HTTRx 250
Roche Enters into Licensing Agreement with Ncardia 251
Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 252
Roche Enters into Licensing Agreement with Halozyme Therapeutics 254
Roche to Enter into Licensing Agreement with Pharmstandard 255
JW Pharma Enters into Licensing Agreement with Chugai Pharma 256
Roche to Enter into Licensing Agreement with Bristol-Myers Squibb 257
Mylan Enters into Licensing Agreement with Genentech and Roche 258
Chugai Pharma Enters into Licensing Agreement with SBI Pharma 259
CiVi Biopharma Enters into Licensing Agreement with F. Hoffmann-La Roche 260
Roche Enters into Licensing Agreement with ImmuNext 261
Genentech Enters into Licensing Agreement with Novimmune 262
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 263
Genentech to Enter into Licensing Agreement with Hanmi Pharma 264
Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 265
Denali Therapeutics Enters Into Licensing Agreement With Genentech 266
Roche Enters into Licensing Agreement with Eleven Biotherapeutics 267
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 268
Chugai Pharma Enters into Licensing Agreement with Two Cells 269
Roche Enters into Licensing Agreement with Blueprint Medicines 270
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 272
F. Hoffmann-La Roche Enters into Licensing Agreement with Shionogi 273
Roche Enters into Licensing Agreement with University of British Columbia and Vancouver Coastal Health Research Institute 274
F. Hoffmann-La Roche Entered into Licensing Agreement with Proximagen 275
Roche Enters into Licensing Agreement with Cellular Dynamics 276
Genentech Enters into Licensing Agreement with Nimbus Therapeutics 277
Genentech Expands Licensing Agreement with Arvinas 278
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 279
Genentech Enters into Licensing Agreement with Almac Discovery 280
Vifor Pharma Expands Licensing Agreement with Roche 281
Curadev Pharma Enters into Licensing Agreement with Roche 282
Phylogica Extends Licensing Agreement with Genentech 283
Genentech to Terminate Licensing Agreement with NewLink Genetics for NLG919 284
Roche Amends Licensing Agreement with Chugai Pharma 286
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 287
Ark Biosciences Enters into Licensing Agreement with Roche for AK0529 288
Chugai Pharma Enters into Licensing Agreement with Roche 289
Roche Expands its Licensing Agreement with Discuva 290
Roche Enters Into Licensing Agreement With Prothena 291
Isarna Therapeutics Enters Into Licensing Agreement With Santaris Pharma To Develop Oligonucleotides For TGF--Mediated Diseases 293
Ocera Therapeutics Enters Into Technology Transfer and License Agreement With F. Hoffmann-La Roche 294
Coherus BioSciences Enters into Licensing Agreement with Genentech 295
RaNA Therapeutics Enters Into Licensing Agreement With Santaris Pharma To Develop RNA-Targeted Medicines 296
Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 297
Santaris Pharma Amends Licensing Agreement With miRagen Therapeutics 298
Clementia Pharma Enters into Licensing Agreement with F. Hoffmann-La Roche 299
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 301
Dutalys Enters Into Licensing Agreement With Global Pharma Company 302
Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 303
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 304
Roche Enters Into Licensing Agreement With Galaxy Biotech For Oncology Program 305
Roche Enters Into Licensing Agreement With Savira Pharma 307
Novogen Enters into Licensing Agreement with Genentech for GDC-0084 308
Maruho Enters into Licensing Agreement with Chugai Pharma 309
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 310
Genentech Enters into Licensing Agreement with Carmot Therapeutics 311
Roche Enters into Licensing Agreement with Amgen 312
F. Hoffmann-La Roche Enters into Licensing Agreement with Pieris Pharma 313
Roche Enters into Licensing Agreement with Dalcor Pharma 314
4D Molecular Therapeutics Enters into Licensing Agreement with Roche 315
Roche Molecular Enters into Licensing Agreement with Qiagen 316
Roche Enters into Licensing Agreement with Meiji Seika Pharma and Fedora Pharma 317
EpiVax Enters into Licensing Agreement with Chugai Pharma 318
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 319
Roche To Enter Into Licensing Agreement With Medicines Patent Pool For Saquinavir 320
Afraxis Enters Into Licensing Agreement With Genentech 321
Research Ventures & Licensing Enters Into Licensing Agreement With Santaris Pharma 322
Techpool Bio-Pharma Enters Into Licensing Agreement With Roche For Antineoplastic Drug 323
Roche Enters Into Licensing Agreement With Seaside Therapeutics For mGluR5 Antagonists 324
AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 325
Roche Extends Licensing Agreement With Genedata 327
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 328
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 329
Foundation Medicine Raises USD250 Million in Private Placement of Shares 330
Ariosa Diagnostics Withdraws IPO 331
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 332
InterMune Completes Public Offering Of Shares For US$282.5 Million 333
InterMune Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For US$97.2 Million 334
Foundation Medicine Completes IPO Of Shares For US$122 Million 335
InterMune Completes Public Offering Of Common Stock For US$154 Million 336
Roche Prices Public Offering of Bonds Due 2020 for USD600 Million 337
Roche Prices Public Offering of 0.875% Bonds Due 2025 for USD1.14 Billion 338
Roche Plans to Raise USD850 Million in Public Offering of Notes 339
Roche Plans to Raise USD500 Million in Public Offering of Bonds 340
Roche Plans to Raise USD1.3 Billion in Public Offering of Bonds Due 2021 341
Roche Plans to Raise USD1.3 Billion in Public Offering of Bonds Due 2024 342
Roche Plans to Raise USD300 Million in Public Offering of Bonds 343
Roche Plans to Raise USD1.5 Billion in Public Offering of Bonds 344
InterMune Completes Public Offering Of Notes Due 2017 For US$137 Million 345
Roche Completes Public Offering Of Bonds Due 2018 For US$658 Million 347
Roche Completes Public Offering Of Bonds Due 2022 For US$548 Million 348
Roche Completes Public Offering Of Bonds Due 2013 For US$438 Million 349
Roche Completes Public Offering Of Bonds Due 2018 For US$1.32 Billion 350
Recipharm Acquires Manufacturing Facility from Roche 351
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 352
Patheon Acquires API Manufacturing Site, South Carolina from Roche 353
F. Hoffmann-La Roche May Sell its Diabetes Care Business 354
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 355
Atnahs Pharma Acquires Naprosyn, Anaprox and Toradol from Roche 356
Pediapharm Acquires Naproxen Suspension from Roche 357
Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD497 Million 358
Vidara Therapeutics International Acquires Actimmune From InterMune For US$55 Million 360
RIEMSER Arzneimittel Acquires Worldwide Rights Of Ostac From Roche 362
Roche to Acquire Remaining Stake in Foundation Medicine for USD2.4 Billion 363
Roche to Acquire Ignyta for USD1.7 Billion 364
Roche Acquires ForSight VISION4 from ForSight Labs 366
Noritsu Koki to Acquire 64.7% Stake in Genentech for USD27 Million 367
Roche Acquires Tensha Therapeutics 368
Pacific Biosciences May Sell Itself 369
Roche Acquires Kapa Biosystems 370
Roche Acquires Adheron Therapeutics 371
Roche Acquires CAPP Medical 372
Roche Acquires Majority Stake in Foundation Medicine for USD1.03 Billion 373
Roche May Acquire BioMarin Pharma 375
Roche Acquires Trophos for USD386 Million 376
Roche Acquires Signature Diagnostics 378
Roche Acquires Bina Technologies 379
Roche Acquires Dutalys for USD489 million 380
Tetraphase Pharma May Sell Itself 381
Roche Acquires InterMune for USD8.3 Billion 382
Roche Acquires Santaris Pharma for USD450 Million 384
Roche Completes Acquisition of Seragon Pharma for USD1.72 Billion 386
Roche May Acquire 40% Stake in Chugai Pharma 387
F. Hoffmann-La Roche Completes Acquisition of Iquum for USD450 Million 388
Roche Diagnostics Acquires Genia for up to USD350 Million 389
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technologys Spin-Out Companies 390
Roche Rumored to Acquire BioMarin Pharma for USD13.5 Billion 391
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 392
Takeda Completes Acquisition Of Remaining 87.5% Stake In Envoy Therapeutics For Up To US$140 Million 394
F. Hoffmann-La Roche Ltd, Key Competitors 396
F. Hoffmann-La Roche Ltd, Key Employees 397
F. Hoffmann-La Roche Ltd, Subsidiaries 398

List Of Figures

List of Figures
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 18
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 19
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 20
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 21
F. Hoffmann-La Roche Ltd, Medical Devices Deals, 2012 to YTD 2018 23

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available